Hypercoagulability in Pulmonary Hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Hematology

Background:

• Pulmonary hypertension (PH) is classified by the WHO into distinct pathophysiological groups.
• Pulmonary arterial hypertension (PAH), a WHO group 1 PH, is a severe condition marked by vasoconstriction, proliferation, and thrombosis.
• PAH leads to elevated pulmonary artery pressure, right heart failure, and mortality.

Purpose of the Study:

• To review the role of thrombosis in PAH pathophysiology.
• To evaluate the current evidence for anticoagulation and antiplatelet therapies in PAH management.

Main Methods:

• Literature review of studies on PAH, thrombosis, coagulation, and platelet function.
• Analysis of pathological findings in small distal pulmonary arteries in PAH patients.
• Synthesis of evidence regarding the efficacy of anticoagulation and antiplatelet agents in PAH.

Main Results:

• In situ thromboses are a key pathological feature in distal pulmonary arteries of PAH patients.
• Coagulation, platelet, and endothelial cell dysregulation contribute to a prothrombotic state in PAH.
• Clinical evidence supporting the routine use of anticoagulation or antiplatelet therapy in PAH remains inconclusive.

Conclusions:

• Thrombosis is integral to PAH pathogenesis, suggesting a potential therapeutic target.
• Further research is needed to clarify the risks and benefits of antithrombotic therapies in PAH.
• The prothrombotic nature of PAH warrants careful consideration of anticoagulation and antiplatelet strategies.